NO20001171L - FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister - Google Patents

FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Info

Publication number
NO20001171L
NO20001171L NO20001171A NO20001171A NO20001171L NO 20001171 L NO20001171 L NO 20001171L NO 20001171 A NO20001171 A NO 20001171A NO 20001171 A NO20001171 A NO 20001171A NO 20001171 L NO20001171 L NO 20001171L
Authority
NO
Norway
Prior art keywords
naturally occurring
procedure
bone volume
increasing bone
selective agonists
Prior art date
Application number
NO20001171A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001171D0 (no
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20001171D0 publication Critical patent/NO20001171D0/no
Publication of NO20001171L publication Critical patent/NO20001171L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20001171A 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister NO20001171L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09
PCT/US1998/018338 WO1999012551A1 (en) 1997-09-09 1998-09-04 Method of increasing bone volume using non-naturally-occurring fp selective agonists

Publications (2)

Publication Number Publication Date
NO20001171D0 NO20001171D0 (no) 2000-03-07
NO20001171L true NO20001171L (no) 2000-05-09

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001171A NO20001171L (no) 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Country Status (20)

Country Link
US (1) US6156799A (tr)
EP (1) EP1045694A1 (tr)
JP (1) JP2001515864A (tr)
KR (1) KR20010023840A (tr)
CN (1) CN1269721A (tr)
AR (1) AR013479A1 (tr)
AU (1) AU739275B2 (tr)
BR (1) BR9811780A (tr)
CA (1) CA2303800A1 (tr)
CO (1) CO4980882A1 (tr)
HU (1) HUP0004581A2 (tr)
ID (1) ID24827A (tr)
IL (1) IL134760A0 (tr)
NO (1) NO20001171L (tr)
PE (1) PE119099A1 (tr)
PL (1) PL339288A1 (tr)
SK (1) SK3412000A3 (tr)
TR (1) TR200000662T2 (tr)
WO (1) WO1999012551A1 (tr)
ZA (1) ZA988228B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
AU763715B2 (en) * 1999-03-05 2003-07-31 Duke University C16 unsaturated fp-selective prostaglandins analogs
AU3711900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
CN1498385A (zh) 2000-08-29 2004-05-19 X图像量析的方法与装置
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
ATE440536T1 (de) 2001-05-25 2009-09-15 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
ES2360604T3 (es) * 2001-07-23 2011-06-07 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
NZ530885A (en) * 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
CN1642503A (zh) * 2002-02-07 2005-07-20 拉特格斯·新泽西州立大学 用于药物送递的治疗聚酐化合物
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
JP2007524438A (ja) 2003-03-25 2007-08-30 イメージング セラピューティクス，インコーポレーテッド 放射線画像処理技術における補償の方法
WO2005027732A2 (en) * 2003-09-19 2005-03-31 Imaging Therapeutics, Inc. Method for bone structure prognosis and simulated bone remodeling
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
WO2006034018A2 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
EP2061376A2 (en) * 2006-09-15 2009-05-27 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
AU3607293A (en) * 1992-02-05 1993-09-03 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
CA2303800A1 (en) 1999-03-18
AR013479A1 (es) 2000-12-27
EP1045694A1 (en) 2000-10-25
TR200000662T2 (tr) 2000-07-21
SK3412000A3 (en) 2000-12-11
PE119099A1 (es) 2000-02-03
ZA988228B (en) 1999-03-09
CO4980882A1 (es) 2000-11-27
HUP0004581A2 (hu) 2001-05-28
NO20001171D0 (no) 2000-03-07
AU739275B2 (en) 2001-10-11
US6156799A (en) 2000-12-05
IL134760A0 (en) 2001-04-30
AU9219298A (en) 1999-03-29
WO1999012551A1 (en) 1999-03-18
PL339288A1 (en) 2000-12-04
CN1269721A (zh) 2000-10-11
ID24827A (id) 2000-08-24
KR20010023840A (ko) 2001-03-26
JP2001515864A (ja) 2001-09-25
BR9811780A (pt) 2000-09-12

Similar Documents

Publication Publication Date Title
NO20001171L (no) FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister
Michelassi et al. Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction
Plonka et al. Zinc as an ambivalent but potent modulator of murine hair growth in vivo–preliminary observations
Raman et al. Pathway-specific variants of AMPA receptors and their contribution to neuronal signaling
Stebbins et al. Prostaglandins contribute to cardiovascular reflexes evoked by static muscular contraction.
Falabella Repigmentation of leukoderma by minigrafts of normally pigmented, autologous skin
Cruwys et al. The role of bradykinin B1 receptors in the maintenance of intra‐articular plasma extravasation in chronic antigen‐induced arthritis
NO934137L (no) Fremgangsmaate for subkutan, suprafascial, pedikulaer, indre fiksering
Reddy et al. Deactivation of CFTR-Cl conductance by endogenous phosphatases in the native sweat duct
Colonna et al. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits
AU2004314922B2 (en) Use of a lyophilisate of dedifferentiated plant cells for skin depigmentation and/or lightening
Houssay et al. Effects of the pineal gland upon the hair cycles in mice
Corrodi et al. The Effect of Nerve Activity on the Depletion of the Adrenergic Transmitter by Inhibitors of Noradrenaline Synthesis 1
DK0840607T3 (da) Ny medicinsk anvendelse
Thomas et al. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex
Korobko Review of current clinical studies of vitiligo treatments
T O'Shaughnessy et al. A1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
Chiarello Full‐face cryo‐(liquid nitrogen) peel
Fusi et al. Ca2+ entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes
Wu et al. The application of electrolysis of depigmented hair using a trichiasis electrolyzer combined with single hair follicle transplantation for the treatment of vitiligo‐associated leukotrichia
Rubi et al. Modulation of the heart's electrical properties by the anticonvulsant drug retigabine
Farnoush et al. Sequential histological changes and mast cell response in skin during chemically‐induced carcinogenesis
Pscheidt et al. Studies on norepinephrine and 5-hydroxytryptamine in various species. Regional distribution in the brain, response to monoamine oxidase inhibitors, comparison of chemical and biological assay methods for norepinephrine
Johansson et al. Histaminergic nerves demonstrated in the skin. A new direct mode of neurogenic inflammation?

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application